NEW YORK--(BUSINESS WIRE)--May 2, 2006--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today that its lead drug candidate, SIGA-246, has begun Phase I human clinical trials. Based on animal testing to date, SIGA believes that this candidate is a potent therapeutic drug against smallpox. The test will examine the safety and pharmacokinetics of SIGA-246 at different dosages in healthy volunteers. SIGA expects to collect all of the data from this study within the next month.
